中心简介：

主要开展血液系统肿瘤（淋巴瘤、血液病、儿童肿瘤等）相关疾病的多学科诊疗、科研和教学工作，设有血液内科与移植、淋巴瘤内科、儿童肿瘤内科组、血液肿瘤放疗等4个专科主诊组，负责患者阶段性专科诊疗；配备淋巴瘤、血液病、儿童肿瘤等4个专病管理组，负责对患者进行全程管理。

特色诊疗：

1.血液病测序与药物监测技术

2.淋巴瘤精准放疗技术

3.儿童常见肿瘤的多学科诊疗

科研攻关：

1.主要承担的科研项目

（1）褪黑素促进MCL-1抑制剂诱导白血病细胞凋亡的分子机制研究，国家自然科学基金，2022

（2）针对弥漫大B细胞淋巴瘤中EZH2-Y641突变体选择性降解剂的发现及机制研究，国家自然科学基金，2022

（3）褪黑素促进 MCL-1 抑制剂诱导白血病细胞凋亡的分子机制研究，安徽省自然科学基金，2022

（4）基于细胞及临床水平的血液肿瘤药物敏感性预测研究，合肥研究院院长基金，2019

2.代表性论文

（1）Jing Yang, Ellen L Weisberg, Shuang Qi, Wei Ni, Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S Magin, Laura Doherty, Wenchao Wang, Jing Liu, Sara J Buhrlage, Qingsong Liu, James D Griffin.Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia. 2022, 36(4): 1048-1057.

（2）Liyi Fu, Fengming Zou, Qingwang Liu, Beilei Wang, Junqing Wang, Huamin Liang, Xiaofei Liang, Jing Liu, Jinjun Shi, Qingsong Liu. An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia. Nanomedicine. 2020, 29: 102283.

（3）Juan Liu, Qianmao Liang, Aoli Wang, Fengming Zou, Ziping Qi, Kailin Yu, Qingwang Liu, Cheng Chen, Jing Liu, Qingsong Liu. Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma.Signal Transduction and Targeted Therapy. 2020, 5(1): 200.

（4）Haiming Dai, Husheng Ding, Kevin L Peterson, X Wei Meng, Paula A Schneider, Katherine LB Knorr, Scott H kaufmann. Measurement of BH3-only protein tolerance. Cell death and differentiation. 2017, 25(2): 282-293.

（5）Haiming Dai,Husheng Ding,X.Wei Meng,Kevin L.Peterson, Paula A. Schneider,Judith E. Karp,and Scott H. Conductive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes&Development. 2015, 29(2): 2140-2152.